Skip to search formSkip to main contentSkip to account menu

ipilimumab

Known as: MOAB-CTLA-4, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, monoclonal antibody CTLA-4 
A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4… 
National Institutes of Health

Related topics

Related topics

16 relations
10 ML ipilimumab 5 MG/ML Injection10 ML ipilimumab 5 MG/ML Injection [Yervoy]CP-675,206CTLA4 protein, human

Narrower (3)

BMS-734016MDX-010Yervoy

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Baseline neutrophil to lymphocyte ratio combined with serum LDH level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population
This article has been accepted for publication and undergone full peer review but has not been through the copyediting… 
2015
2015
Ipilimumab Induced Encephalitis: A Case Report
Background: Cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) is a helper T cell protein receptor that down regulates the… 
2015
2015
Survival, biomarker, and toxicity analysis of nivolumab (NIVO) in patients that progressed on ipilimumab (IPI).
9055 Background: PD-1 antibodynivolumab was administered with/without a multi-peptide vaccine to 126 patients (pts) with… 
2014
2014
Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.
TPS3114 Background: Nivolumab, a fully human IgG4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, and ipilimumab… 
Review
2013
Review
2013
Key issues in the management of gastrointestinal immune-related adverse events associated with ipilimumab administration
Ipilimumab is an anticytotoxic T lymphocyte antigen-4 (CTLA-4) monoclonal antibody that attenuates negative signaling from CTLA-4… 
2012
2012
Recent successes of cancer immunotherapy: a new dimension in personalized medicine?
Until recently, cancer therapy was limited to “debulking approaches” including surgery, chemo–radio- and hormono-therapy and… 
2012
2012
Drug approvals 2011: focus on companion diagnostics.
.S. Food and Drug Administration officials and cancer care advocacy groups are hailing 2011 as a milestone year in the… 
2008
2008
Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody
3008 Background: Ipilimumab represents a new class of immunotherapeutic agent. Antitumor activity (CR, PR, or SD) to ipilimumab… 
2008
2008
Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine
9022 Background: Ipilimumab is a fully human monoclonal antibody targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) that gave… 
2008
2008
Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment
3020 Background: Antitumor immune responses have been observed in response to ipilimumab (ipi), an anti-cytotoxic T lymphocyte… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)